The study
analyzed that the T-cell immunotherapy pipeline comprised of 139 therapeutic
candidates, of which 16 are in Phase II stage of development. The high
prevalence of cancer across the globe fuels the extensive research and
development for the T-cell immunotherapeutic. T-cell immunotherapy is emerging
as novel and promising approach for the treatment of cancer. It is gaining huge
traction globally, for its several advantages over conventional therapies such
as very low or no side effects and high specificity.
CAR
T-cells are the modified T-cells used to express CARs, which recognize specific
antigens present on targeted cell. CARs are specifically designed synthetic
receptors, linked with the single-chain variable fragment (scFV) of a
monoclonal antibody. The domain includes T-cell receptor CD3-zeta chain, which
graft specificity into an immune effector cell. It mediates T-cell cytotoxicity
and activation when bound to a target cell.
The
research finds that the different companies are collaborating for the
development of T-cell immunotherapeutic. In June 2015, Celgene Corporation and
Juno Therapeutics, Inc. collaborated for the development and commercialization
of immunotherapies.
Some of
the key players developing T-cell immunotherapies are Novartis AG, Cellular
Biomedicine Group, Inc., Kite Pharmaceuticals Inc. and others.
Explore
Report Sample at: https://www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis/report-sample
The
research finds that the different companies are collaborating for the
development of T-cell immunotherapeutic. In June 2015, Celgene Corporation and
Juno Therapeutics, Inc. collaborated for the development and commercialization
of immunotherapies. The two companies will leverage T-cell therapeutic
strategies to develop treatments for patients with cancer and autoimmune
diseases with an initial focus on CAR T and TCR technologies. Some of the key
players developing T-cell immunotherapies are Novartis AG, Cellular Biomedicine
Group, Inc., Kite Pharmaceuticals Inc., Juno Therapeutics, Inc., Gradalis,
Inc., Atara Biotherapeutics, Inc., Adaptimmune Therapeutics Plc., Immunocore
Limited, and Lion Biotechnologies, Inc.
